Alitretinoin

Generic Name: Alitretinoin

Brand Names: Panretin

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₈O_₂

CAS Number: 5300-03-8

Unique Ingredient Identifier: 1UA8E65KDZ

Background: An important regulator of gene expression during growth and development, and in neoplasms. Tretinoin, also known as retinoic acid and derived from maternal vitamin A, is essential for normal growth; and embryonic development. An excess of tretinoin can be teratogenic. It is used in the treatment of psoriasis; acne vulgaris; and several other skin diseases. I...

Indication: 外用可用于局部治疗艾滋病相关的卡波西肉瘤且未接受全身治疗的皮肤损伤。口服可用于局部外用强效糖皮质激素无效的慢性手部湿疹患者。

Associated Conditions: Chronic Eczema of the hand, Cutaneous lesions, Refractory Eczema of the hand, Severe Eczema of the hand

Associated Therapies: -

Clinical Trials

Alitretinoin vs Cyclosporine in Severe Recurrent Vesicular Hand Eczema

Phase 3

Conditions: Hand Eczema

Interventions: Drug: Alitretinoin
Drug: cyclosporin A

First Posted Date: 2017-01-20

Last Posted Date: 2019-02-26

Lead Sponsor: University Medical Center Groningen

Target Recruit Count: 76

Registration Number: NCT03026946

Locations: 🇳🇱
University Medical Center Groningen, Groningen, Netherlands

Alitretinoin vs Azathioprine in Severe Non-hyperkeratotic Hand Eczema

Phase 3

Conditions: Hand Eczema

Interventions: Drug: Azathioprine
Drug: Alitretinoin

First Posted Date: 2017-01-20

Last Posted Date: 2018-05-04

Lead Sponsor: University Medical Center Groningen

Target Recruit Count: 116

Registration Number: NCT03026907

Locations: 🇳🇱
University Medical Center Groningen, Groningen, Netherlands

Single Dose of 9-cis-retinoic Acid in Hepatic Patients

Completed

Conditions: Hepatic Insufficiency

Interventions: Drug: 9-cis-retinoic acid

First Posted Date: 2013-07-03

Last Posted Date: 2013-07-03

Lead Sponsor: University Hospital, Gentofte, Copenhagen

Target Recruit Count: 20

Registration Number: NCT01891526

Locations: 🇩🇰
Gentofte Hospital, Gentofte, Denmark

Lichen Planus Mucosae at USZ, Efficacy of Oral Alitretinoin

Phase 2

Conditions: Lichen Planus (LP)

First Posted Date: 2012-02-24

Last Posted Date: 2012-03-20

Lead Sponsor: University of Zurich

Target Recruit Count: 20

Registration Number: NCT01538732

Locations: 🇨🇭
University Hospital Zurich, Division of Dermatology, Zurich, ZH, Switzerland

Efficacy and Safety of Oral Alitretinoin (Toctino®) in the Treatment of Patients With Cutaneous Lupus Erythematosus

Phase 2

Terminated

Conditions: Lupus Erythematosus, Cutaneous

Interventions: Drug: Alitretinoin

First Posted Date: 2011-08-02

Last Posted Date: 2016-06-01

Lead Sponsor: University Hospital Muenster

Target Recruit Count: 7

Registration Number: NCT01407679

Locations: 🇩🇪
Department of Dematology, University Hospital, Mannheim, Baden-Wuerttemberg, Germany
🇩🇪
Department of Dermatology, Ludwig-Maximilians University, Muenchen, Bayern, Germany
🇩🇪
Department of Dermatology, University Hospital, Muenster, Westfalen, Germany

Pharmacokinetics of 9-cis-retinoic Acid (Alitretinoin, Toctino®) in Patients With Hepatic Disease

Phase 1

Completed

Conditions: Hepatic Insufficiency

Interventions: Drug: Alitretinoin

First Posted Date: 2010-12-17

Last Posted Date: 2013-01-29

Lead Sponsor: University Hospital, Gentofte, Copenhagen

Target Recruit Count: 16

Registration Number: NCT01261923

Locations: 🇩🇰
Gentofte Hospital, Hellerup, Denmark

Efficacy of Alitretinoin Treatment in Patients With Pustular Form of Psoriasis

Phase 2

Completed

Conditions: Psoriasis

Interventions: Drug: alitretinoin
Drug: Placebo

First Posted Date: 2010-11-22

Last Posted Date: 2017-12-21

Lead Sponsor: Stiefel, a GSK Company

Target Recruit Count: 33

Registration Number: NCT01245140

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

Ciclosporin Versus Alitretinoin for Severe Atopic Hand Dermatitis.

Phase 4

Terminated

Conditions: Atopic Dermatitis

Interventions: Drug: Alitretinoin
Drug: Ciclosporin

First Posted Date: 2010-11-01

Last Posted Date: 2014-06-03

Lead Sponsor: Technische Universität Dresden

Target Recruit Count: 15

Registration Number: NCT01231854

Locations: 🇩🇪
Universitätsklinikum Carl Gustav Carus an der TU Dresden, Dresden, Sachsen, Germany

Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema

Phase 3

Completed

Conditions: Eczema

Interventions: Drug: alitretinoin
Drug: Placebo

First Posted Date: 2009-01-06

Last Posted Date: 2020-04-27

Lead Sponsor: Stiefel, a GSK Company

Target Recruit Count: 599

Registration Number: NCT00817063

Locations: 🇺🇸
Bernstein Clinical Research Center, Cincinnati, Ohio, United States
🇺🇸
Dermatology Clinical Research Center of San Antonio, San Antonio, Texas, United States
🇺🇸
Kansas City Dermatology, PA, Overland Park, Kansas, United States

and more 66 locations

Alitretinoin in the Treatment of Chronic Hand Eczema

Phase 3

Completed

Conditions: Eczema

First Posted Date: 2007-08-23

Last Posted Date: 2023-05-10

Lead Sponsor: Basilea Pharmaceutica

Target Recruit Count: 150

Registration Number: NCT00519675

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy